Royalty Pharma to Announce Second Quarter 2023 Financial Results on August 8, 2023
19 7월 2023 - 5:15AM
Royalty Pharma plc (Nasdaq: RPRX) today announced that it will
report its second quarter 2023 financial results on Tuesday, August
8, 2023 before the U.S. financial markets open. The company will
host a conference call and simultaneous webcast at 8:00 a.m.
Eastern Time that day.
Conference Call Information
Please visit the “Investors” page of the company’s website at
https://www.royaltypharma.com/investors/news-and-events/events to
obtain conference call information and to view the live webcast. A
replay of the conference call and webcast will be archived on the
company's website for at least 30 days.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of
biopharmaceutical royalties and a leading funder of innovation
across the biopharmaceutical industry, collaborating with
innovators from academic institutions, research hospitals and
non-profits through small and mid-cap biotechnology companies to
leading global pharmaceutical companies. Royalty Pharma has
assembled a portfolio of royalties which entitles it to payments
based directly on the top-line sales of many of the industry’s
leading therapies. Royalty Pharma funds innovation in the
biopharmaceutical industry both directly and indirectly - directly
when it partners with companies to co-fund late-stage clinical
trials and new product launches in exchange for future royalties,
and indirectly when it acquires existing royalties from the
original innovators. Royalty Pharma’s current portfolio includes
royalties on more than 35 commercial products, including Vertex’s
Trikafta, Kalydeco, Orkambi and Symdeko, Biogen’s Tysabri and
Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas
and Pfizer’s Xtandi, GSK’s Trelegy, Novartis’ Promacta, Pfizer’s
Nurtec ODT, Johnson & Johnson’s Tremfya, Roche’s Evrysdi,
Gilead’s Trodelvy, and 11 development-stage product candidates. For
more information, visit www.royaltypharma.com.
Royalty Pharma Investor Relations and
Communications
+1 (212) 883-6637ir@royaltypharma.com
Royalty Pharma (NASDAQ:RPRX)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Royalty Pharma (NASDAQ:RPRX)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024